Clinical trials for predictive medicine: New challenges and paradigms

Clinical Trials

Volumn 7, Issue 5, 2010, Pages 516-524

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL STUDY; CONFERENCE PAPER; DRUG DEVELOPMENT; GENOMICS; HEALTH CARE COST; MOLECULARLY TARGETED THERAPY; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELIABILITY; VALIDATION PROCESS;

CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 78649965504     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510366454     Document Type: Conference Paper

References (23)

1. Pepe MS, Janes H., Longton G., et al. Limitations of the odds ratio in guaging the performance of a diagnostic, prognostic or screening marker. Am J Epidemiol 2004 ; 159: 882-90.
2. Harrell FE Regression Modeling Strategies. Springer-Verlag, New York, 2001.
3. Molinaro AM, Simon R., Pfeiffer RM Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005 ; 21 (15). 3301-7.
4. Simon R. An agenda for clinical trials: clinical trials in the genomic era. Clin Trials 2004 ; 1: 468-70.
5. Simon R. New challenges for 21st century clinical trials. Clin Trials 2007 ; 4: 167-9.
6. Peto R., Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Brit J Cancer 1976 ; 34: 585-612.
7. Peto R., Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. Brit J Cancer 1977 ; 35: 1-39.
8. Group I-C. Randomised trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988 ; 349-60.
9. Sawyers CL The cancer biomarker problem. Nature 2008 ; 452: 548-52.
10. Karapetis CS, Khambata-Ford S., Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 2008 ; 359: 1757-65.
11. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004 ; 351: 2817-26.
12. van-de-Vijver MJ, He YD, Veer LJvt, et al. A gene expression signature as a predictor of survival in breast cancer. New Engl J Med 2002 ; 347: 1999-2009.
13. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005 ; 23: 7332-41.
14. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Stati Med 2005 ; 24: 329-39.
15. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2005 ; 10: 6759-63.
16. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clin Cancer Res 2006 ; 12: 3229.
17. Simon R. Using genomics in clinical trial design. Clin Cancer Res 2008 ; 14: 5984-93.
18. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Rev Mol Diagn 2008 ; 2: 721-9.
19. Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007 ; 6: 227-44.
20. Jiang W., Freidlin B., Simon R. Biomarker adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer I 2007 ; 99: 1036-43.
21. Freidlin B., Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005 ; 11: 7872-8.
22. Freidlin B., Jiang W., Simon R. The cross-validated adaptive signature design for predictive analysis of clinical trials. Clin Cancer Res 2010 ; 16: 691-6.
23. Simon R. Bayesian subset analysis: application to studying treatment-by-gender interactions. Stat Med 2002 ; 21: 2909-16.